[
  {
    "indication": "adults with severe alopecia areata",
    "approval_date": "2022-06-13",
    "year": 2022,
    "confidence": "high",
    "source_text": "FDA Approves Lilly and Incyte's Olumiant (baricitinib) as First and Only Systemic Medicine for Adult"
  },
  {
    "indication": "covid-19 in certain hospitalized adults",
    "approval_date": "2022-05-11",
    "year": 2022,
    "confidence": "high",
    "source_text": "FDA Approves Olumiant (baricitinib) Treatment for COVID-19 in Certain Hospitalized Adults"
  },
  {
    "indication": "adults with moderately-to-severely active rheumatoid arthritis",
    "approval_date": "2018-06-01",
    "year": 2018,
    "confidence": "high",
    "source_text": "FDA Approves Olumiant (baricitinib) 2 mg Tablets for the Treatment of Adults with Moderately-to-Seve"
  },
  {
    "indication": "moderately-to-severely active rheumatoid arthritis",
    "approval_date": "2018-04-23",
    "year": 2018,
    "confidence": "high",
    "source_text": "FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of"
  }
]